On January 2, 2018 H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of next generation cancer medicines using data science and precision chemistry product engine, reported that Markus Warmuth, M.D., President and CEO of H3 Biomedicine, will present an overview of the company and its 2018 goals at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018, at 9:00 a.m. (PST) at the Westin St. Francis Hotel in San Francisco (Press release, H3 Biomedicine, JAN 2, 2018, View Source [SID1234522809]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the presentation, Dr. Warmuth is expected to provide details about the company’s data science and precision chemistry product engine and its clinical pipeline of three differentiated, internally-generated cancer therapies, including:

H3B-8800, an oral, potent and selective small molecule modulator of splicing factor 3b subunit 1 (SF3B1) that is being developed by H3 Biomedicine as an anticancer therapeutic agent.
H3B-6527, a selective, orally bioavailable, and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4) that is being investigated for the treatment of advanced hepatocellular carcinoma (HCC).
H3B-6545, an orally bioavailable, potent and selective small molecule modulator of wild-type and mutant Estrogen Receptor (ERα).
For more information about H3 Biomedicine’s pipeline, click here.